SCHEMBL26985990

SCHEMBL26985990

COc1ccc(COCC(O)CCO)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.69
CA2 P00918 2/20 0.69
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 1/20 0.45
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
ATM Q13315 1/20 0.44
CASR P41180 1/20 0.43
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
POLB P06746 1/20 0.42
SLC6A4 P31645 1/20 0.42
TBXAS1 P24557 1/20 0.42
APP P05067 2/20 0.41
ADRB3 P13945 2/20 0.41
ADRB2 P07550 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31506185 1.00 CA1 (0.69) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL31506240 1.00 CA1 (0.69) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL9184887 0.87 CA1 (0.69) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL14538696 0.87 CA1 (0.73) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL1194332 0.87 CA1 (0.73) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL1194330 0.87 CA1 (0.73) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL26986081 0.86 CA1 (0.55) CA1CA2IDO1AGXTCASR
SCHEMBL8082823 0.84 CA1 (0.70) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL13109585 0.83 CA1 (0.73) CA1CA2MEN1ALDH1A1KMT2A
SCHEMBL24634748 0.81 CA1 (0.70) CA1CA2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX CA1 1416/4885CA2 1189/4885MEN1 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.